- Home
- FGI vs CANF Comparison
FGI vs CANF Comparison
Compare FGI & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FGI | CANF |
|---|---|---|
| Founded | 1987 | 1994 |
| Country | United States | Israel |
| Employees | 420 | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5M | 7.2M |
| IPO Year | N/A | 2011 |
Fundamental Metrics
Financial Performance| Metric | FGI | CANF |
|---|---|---|
| Price | $5.32 | $3.38 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $50.00 |
| AVG Volume (30 Days) | 113.6K | ★ 940.9K |
| Earning Date | 04-09-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.38 | $2,715,455.50 |
| Revenue Next Year | $6.06 | $101.06 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.50 | $0.17 |
| 52 Week High | $12.62 | $10.40 |
Technical Indicators
Market Signals| Indicator | FGI | CANF |
|---|---|---|
| Relative Strength Index (RSI) | 46.18 | 53.63 |
| Support Level | $4.84 | $2.89 |
| Resistance Level | $5.45 | $4.74 |
| Average True Range (ATR) | 0.68 | 0.28 |
| MACD | -0.20 | 0.01 |
| Stochastic Oscillator | 25.39 | 45.12 |
Price Performance
Historical ComparisonAbout FGI FGI Industries Ltd.
FGI Industries Ltd is a supplier of kitchen and bath products. The company is business to business supplier of bath and kitchen products to large retail, wholesale, commercial, and specialty channel customers around the globe. The company offers products that fall into four categories: Sanitaryware, Bath Furniture, Shower Systems and Other. The company generates the majority of its revenue from the sale of Sanitaryware products. Geographically, the company generates the majority of its revenue from the United States, followed by Canada and Europe.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.